【佳學(xué)基因檢測(cè)】醫(yī)師資格考試中，如何準(zhǔn)備關(guān)于ADRA1B的相關(guān)內(nèi)容？

基因檢測(cè)的序列名稱：

ADRA1B

人體基因序列變化與疾病表征數(shù)據(jù)庫(kù)中的基因代碼：

147

人體基因序列數(shù)據(jù)庫(kù)中國(guó)際交流名稱全稱

adrenoceptor alpha 1B

中國(guó)數(shù)據(jù)庫(kù)中基因全稱：

腎上腺素受體1B

基因檢測(cè)報(bào)告英文版基因簡(jiǎn)介

Alpha-1-adrenergic receptors (alpha-1-ARs) are members of the G protein-coupled receptor superfamily. They activate mitogenic responses and regulate growth and proliferation of many cells. There are 3 alpha-1-AR subtypes: alpha-1A, -1B and -1D, all of which signal through the Gq/11 family of G-proteins and different subtypes show different patterns of activation. This gene encodes alpha-1B-adrenergic receptor, which induces neoplastic transformation when transfected into NIH 3T3 fibroblasts and other cell lines. Thus, this normal cellular gene is identified as a protooncogene. This gene comprises 2 exons and a single large intron of at least 20 kb that interrupts the coding region. [provided by RefSeq, Jul 2008]

基因突變所影響的基因信息

Alpha-1-腎上腺素受體（alpha-1-ARs）是G蛋白偶聯(lián)受體超家族的成員。它們激活有絲分裂反應(yīng)并調(diào)節(jié)許多細(xì)胞的生長(zhǎng)和增殖。存在3種alpha-1-AR亞型：alpha-1A，-1B和-1D，它們均通過G蛋白的Gq / 11家族發(fā)出信號(hào)，不同的亞型顯示出不同的激活模式。該基因編碼α-1B-腎上腺素能受體，當(dāng)轉(zhuǎn)染到NIH 3T3成纖維細(xì)胞和其他細(xì)胞系中時(shí)會(huì)誘導(dǎo)腫瘤轉(zhuǎn)化。因此，該正常細(xì)胞基因被鑒定為原癌基因。該基因包含2個(gè)外顯子和一個(gè)至少20 kb的大內(nèi)含子，可中斷編碼區(qū)。[由RefSeq提供，200??

國(guó)際國(guó)內(nèi)該堿基因序列的其他英語(yǔ)文字母簡(jiǎn)稱：

ADRA1, ALPHA1BAR

基因解碼對(duì)該基因序列在細(xì)胞核中的染色體所給予的編號(hào)：

該基因序列位于人類第5號(hào)染色體上。

基因解碼對(duì)基因序列的正確定位

該基因序列在GRCh37版本中的起始位置坐標(biāo)為：159343740；結(jié)束位置坐標(biāo)為：159400017。該基因序列在GRCh38版本中的起始位置坐標(biāo)為：159916733；結(jié)束位置坐標(biāo)為：159989205。正確的基因信息定位是基因檢測(cè)和對(duì)檢測(cè)結(jié)果進(jìn)行正確解讀的關(guān)鍵。

佳學(xué)基因解碼對(duì)該基因的功能分類：國(guó)際版

G-protein coupled receptors/GPCRs excl olfactory receptors

基因解碼對(duì)該基因的功能分類：中文版

G 蛋白偶聯(lián)受體/GPCR 不包括嗅覺受體

結(jié)構(gòu)與功能基因解碼所揭示的該基因在細(xì)胞內(nèi)發(fā)揮作用的場(chǎng)所（國(guó)際版）：

Plasma membrane(Supported)

結(jié)構(gòu)與功能基因解碼所揭示的該基因發(fā)揮作用的細(xì)胞內(nèi)位置（中文版）：

質(zhì)膜

該基因序列變化后增加的疾病風(fēng)險(xiǎn)（國(guó)際版）：

Neurotoxicity Syndromes; Hypotension; Cardiomegaly; Kidney Diseases; Nerve Degeneration; Mood Disorders; Seizures; Liver Cirrhosis, Experimental

如果該基因突變后，風(fēng)險(xiǎn)可能增加的疾病類型（中文版）：

神經(jīng)毒性綜合征；低血壓;心臟肥大；腎臟疾??；神經(jīng)退化；情緒障礙；癲癇發(fā)作；肝硬化實(shí)驗(yàn)性

GWAS基因檢測(cè)所建立的與該基因的疾病關(guān)聯(lián)（國(guó)際版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請(qǐng)關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫(kù)的更新內(nèi)容

GWAS基因檢測(cè)所解碼的該基因突變會(huì)增加風(fēng)險(xiǎn)的疾病種類（中文版）：

正在通過基因解碼技術(shù)進(jìn)行收集、查證并編輯，請(qǐng)關(guān)注佳學(xué)基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫(kù)的更新內(nèi)容

以該基因做靶點(diǎn)的藥物（國(guó)際版）：

Midodrine (Protein heterodimerization activity);Ziprasidone (Protein heterodimerization activity);Cabergoline (Protein heterodimerization activity);Dapiprazole (Protein heterodimerization activity);Amitriptyline (Protein heterodimerization activity);Olanzapine (Protein heterodimerization activity);Alfuzosin (Protein heterodimerization activity);Clozapine (Protein heterodimerization activity);Norepinephrine (Protein heterodimerization activity);Phenylephrine (Protein heterodimerization activity);Loxapine (Protein heterodimerization activity);Promazine (Protein heterodimerization activity);Prazosin (Protein heterodimerization activity);Imipramine (Protein heterodimerization activity);Chlorpromazine (Protein heterodimerization activity);Nortriptyline (Protein heterodimerization activity);Clonidine (Protein heterodimerization activity);Doxazosin (Protein heterodimerization activity);Nicardipine (Protein heterodimerization activity);Epinephrine (Protein heterodimerization activity);Thioridazine (Protein heterodimerization activity);Ergotamine (Protein heterodimerization activity);Tamsulosin (Protein heterodimerization activity);Methoxamine (Protein heterodimerization activity);Trimipramine (Protein heterodimerization activity);Risperidone (Protein heterodimerization activity);Modafinil (Protein heterodimerization activity);Propiomazine (Protein heterodimerization activity);Fenoldopam (Protein heterodimerization activity);Phenoxybenzamine (Protein heterodimerization activity);Oxymetazoline (Protein heterodimerization activity);Carvedilol (Protein heterodimerization activity);Doxepin (Protein heterodimerization activity);Nefazodone (Protein heterodimerization activity);Terazosin (Protein heterodimerization activity);Pergolide (Protein heterodimerization activity);Bromocriptine (Protein heterodimerization activity);Quetiapine (Protein heterodimerization activity);Aripiprazole (Protein heterodimerization activity);Lisdexamfetamine (Protein heterodimerization activity);Paliperidone (Protein heterodimerization activity);Methotrimeprazine (Protein heterodimerization activity);Dextroamphetamine (Protein heterodimerization activity);Phendimetrazine (Protein heterodimerization activity);Propericiazine (Protein heterodimerization activity);Acepromazine (Protein heterodimerization activity);Thioproperazine (Protein heterodimerization activity);Dronedarone (Protein heterodimerization activity);R450 (Protein heterodimerization activity);Epicept NP-1 (Protein heterodimerization activity);Sertindole (Protein heterodimerization activity);Silodosin (Protein heterodimerization activity);Droxidopa (Protein heterodimerization activity);Xylometazoline (Protein heterodimerization activity);Brexpiprazole (Protein heterodimerization activity);Cirazoline (Protein heterodimerization activity)

針對(duì)該基因所產(chǎn)生的突變，可能有正確效果的藥物（中文版）：

米多君（蛋白質(zhì)異二聚活性）；齊拉西酮（蛋白質(zhì)異二聚活性）；卡麥角林（蛋白質(zhì)異二聚活性）；達(dá)哌唑（蛋白質(zhì)異二聚活性）；阿米替林（蛋白質(zhì)異二聚活性）；奧氮平（蛋白質(zhì)異二聚活性）；阿夫唑嗪（蛋白質(zhì)異二聚活性）；氯氮平(蛋白質(zhì)異二聚活性);去甲腎上腺素(蛋白質(zhì)異二聚活性);去氧腎上腺素(蛋白質(zhì)異二聚活性);洛沙平(蛋白質(zhì)異二聚活性);丙嗪(蛋白質(zhì)異二聚活性);哌唑嗪(蛋白質(zhì)異二聚活性);丙咪嗪(蛋白質(zhì)異二聚活性);氯丙嗪(蛋白質(zhì)異二聚活性);去甲替林(蛋白質(zhì)異二聚活性);可樂定(蛋白質(zhì)異二聚活性);多沙唑嗪(蛋白質(zhì)異二聚活性);尼卡地平(蛋白質(zhì)異二聚活性);腎上腺素(蛋白質(zhì)異二聚活性);硫利達(dá)嗪(蛋白質(zhì)異二聚活性);麥角胺(蛋白質(zhì)異二聚活性)異二聚活性);坦索羅辛(蛋白質(zhì)異二聚活性);甲氧明(蛋白質(zhì)異二聚活性);曲米帕明(蛋白質(zhì)異二聚活性);利培酮(蛋白質(zhì)異二聚活性);莫達(dá)非尼(蛋白質(zhì)異二聚活性);丙哌嗪(蛋白質(zhì)異二聚活性);非諾多泮(蛋白質(zhì)異二聚活性)活性);苯氧芐胺(蛋白質(zhì)異二聚活性);羥甲唑啉(蛋白質(zhì)異二聚活性);卡維地洛(蛋白質(zhì)異二聚活性);多塞平(蛋白質(zhì)異二聚活性);奈法唑酮(蛋白質(zhì)異二聚活性);特拉唑嗪(蛋白質(zhì)異二聚活性);培高利特(蛋白質(zhì)異二聚活性) );溴隱亭(蛋白質(zhì)異二聚活性);喹硫平(蛋白質(zhì)異二聚活性);阿立哌唑(蛋白質(zhì)異二聚活性);Lisdexamfetamine(蛋白質(zhì)異二聚活性);帕潘立酮(蛋白質(zhì)異二聚活性);甲氧美拉嗪(蛋白質(zhì)異二聚活性);右苯丙胺(蛋白質(zhì)異二聚活性) ;苯二甲曲嗪（蛋白質(zhì)異二聚活性）;丙哌嗪（蛋白質(zhì)異二聚活性）;乙酰丙嗪（蛋白質(zhì)異二聚活性）;硫丙哌嗪（蛋白質(zhì)異二聚活性）;決奈達(dá)?。ǖ鞍踪|(zhì)異二聚活性）;R450（蛋白質(zhì)異二聚活性）;Epicept NP-1（蛋白質(zhì)異二聚活性）活性);舍吲哚(蛋白質(zhì)異二聚活性);西洛多辛(蛋白質(zhì)異二聚活性);屈昔多巴(蛋白質(zhì)異二聚活性);賽洛唑啉(蛋白質(zhì)異二聚活性);Brexpiprazole(蛋白質(zhì)異二聚活性);西拉唑啉(蛋白質(zhì)異二聚活性)